



# Hiray Awarded Biolake API Production Cooperation Base Status

Nov. 6, 2021



On November 6, 2021, Wuhan National Biological Industry Base Office awarded “Biolake API Production Cooperation Base” status to Hiray Pharma Solutions in a ceremony at Hiray headquarters in Jingmen, China. This award acknowledges Hiray Pharma Solutions is an important base for innovative API development and production in central China. The ceremony was officiated by Mr. Qian Deping, Executive

Deputy Director of Wuhan National Biological Office, Mr. Wu Yingbiao, of the Jingmen Municipal Government, Mr. Wang Wei, Deputy Secretary of Jingmen High-tech Zone, and Mr. Max Chen, Chairman of Wuhan Haite Biopharmaceutical Co.

Director Qian Deping said in his speech that Optics Valley BioLake Research Park will rely on Hiray Pharma Solutions' strong production capability to make up for the park's shortcomings in API synthesis and production. In addition, Hiray will enhance competitiveness by providing domestic and foreign innovative



drug companies with end-to-end services, such as pre-clinical research, clinical research, registration filing, and commercial production of drugs.



One of the important agendas of this ceremony was the signing of strategic cooperation agreements between Hiray Pharmaceutical Solutions and three other enterprises, namely Duorui Pharmaceuticals, Qirui Pharma and Conform Pharma, to open a new chapter of cooperation for API production at Optics Valley BioLake Research Park.

Hiray Pharma Solutions was awarded “Biolake API Production Cooperation Base” status, which will complement the advantages of the innovative pharmaceutical enterprises in the Optics Valley BioLake Research Park working hand-in-hand to seek common development of medicines that will help the world.

